Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,416 across all filing types
Latest filing 2026-06-10 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Sanofi fait le point sur l’étude de phase 3 MOBILIZE, qui évalue le riliprubart dans la polyneuropathie inflammatoire démyélinisante chronique
Regulatory Filings Classification · 85% confidence The document is a corporate press release (“Communiqué de presse”) announcing the discontinuation of a phase 3 clinical trial (MOBILIZE) and providing background on the study and forward‐looking statements. It contains no financial statements, no board or management changes, no earnings figures, and no specific regulatory form filings. It is not an investor presentation, earnings release, or report publication notice. It is a general corporate/regulatory announcement and thus falls into the fallback category for miscellaneous filings: Regulatory Filings (RNS).
2026-06-10 French
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Regulatory Filings Classification · 70% confidence The document is a corporate press release announcing the termination of a clinical trial (MOBILIZE phase 3 study) and contains forward-looking statements but no substantive financial data, no meeting materials, no vote results, no filings of regulatory forms, no financial statements or governance changes. It is an external announcement rather than a formal report or filing type (e.g., 10-K, IR, ER). It therefore falls into the fallback category for general announcements and regulatory press releases.
2026-06-10 English
6-K
Regulatory Filings Classification · 87% confidence The document is a U.S. SEC Form 6-K (“Report of Foreign Private Issuer”) filed by Sanofi, attaching a press release as Exhibit 99.1. It does not contain substantive financial statements or management discussion, but is a regulatory filing under the Securities Exchange Act. This aligns with the fallback category for miscellaneous filings (“Regulatory Filings”).
2026-06-08 English
Communiqué de presse : Sarclisa en formulation sous-cutanée de Sanofi approuvé dans l’UE comme premier traitement anticancéreux administré via un injecteur portable
Regulatory Filings Classification · 15% confidence The document is a corporate press release (communiqué de presse) announcing regulatory approval of a drug formulation. It contains no financial results, no investor Q&A, no management changes, no voting matters, etc. It does not fit any specific reporting category like earnings release, annual report, regulatory certification, or investor presentation. As a general corporate announcement not fitting other categories, it falls under the fallback “Regulatory Filings” category (RNS).
2026-06-08 French
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the European Commission’s approval of Sarclisa subcutaneous formulation, describing clinical studies and marketing details. It is not a financial report, earnings release, ESG disclosure, shareholder meeting material, or management change notice. It is a general regulatory announcement about product approval, which falls under the fallback category “Regulatory Filings (RNS).”
2026-06-08 English
Communiqué de presse : Sanofi lance son plan mondial 2026 d’actionnariat salarié
Share Issue/Capital Change Classification · 95% confidence The document is a press release announcing Sanofi’s global employee shareholding plan (“Action 2026”), detailing the terms of a new share issuance reserved for employees, subscription price, discount, number of new shares, legal and subscription conditions, and admission to trading of the new shares. This is a capital change announcement specifically regarding a share issue. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-06-04 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.